Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.84 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | HRH2 | P25021 | 1/20 | 0.84 |
| ▸ | HTR2A | P28223 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL3098149 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6472968 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL2403972 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL110955 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL36881 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1560185 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL29873356 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024199 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024194 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1989702 | 0.93 | CHRM3 (0.88) | CHRM3ADRB2CHRM2CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293329-A1 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | COSMAXPHARMA CO.,LTD. (KR) | 2024-09-05 | — | — | US | claimed |
| US-11759420-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2023-09-19 | — | — | US | claimed |
| US-20220331243-A1 | INHALABLE PARTICLES | CRYSTEC LTD (GB) | 2022-10-20 | — | — | US | claimed |
| US-11351115-B2 | Inhalable particles | CRYSTEC LTD (GB) | 2022-06-07 | — | — | US | claimed |
| US-20200230053-A1 | Inhalable Particles | CRYSTEC LTD (GB) | 2020-07-23 | — | — | US | claimed |
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20170056325-A1 | Improvements Relating To Inhalable Particles | CRYSTEC LTD (GB) | 2017-03-02 | — | — | US | claimed |
| EP-3104848-A1 | IMPROVEMENTS RELATING TO INHALABLE PARTICLES | Crystec Ltd. (GB) | 2016-12-21 | — | — | EP | claimed |
| EP-1927585-B1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | INTERQUIM SA (ES) | 2016-07-27 | — | — | EP | claimed |
| CN-1903833-A | Method of preparing tuoteludin and its L-tartarate | SHANGHAI COLLEGE OF APPLIED TE (CN) | 2007-01-31 | — | — | CN | claimed |
| CN-1558756-A | Pharmaceutical compositions for the treatment of urinary disorders | �ź㴫 | 2004-12-29 | — | — | CN | claimed |
| EP-1441706-A2 | ANTIMUSCARINIC AEROSOL | Pharmacia & Upjohn Company (US) | 2004-08-04 | — | — | EP | claimed |
| EP-1438035-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY DISORDERS | Pharmacia AB (SE) | 2004-07-21 | — | — | EP | claimed |
| WO-2003026564-A9 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY DISORDERS | PHARMACIA AB (SE) | 2004-06-17 | — | — | WO | claimed |
| US-20040116533-A1 | Mixtures of testosterone 5 alpha -reductase inhibitors, adrenergic, muscarinic and serotonin receptor antagonists, and optionally carriers or dilunts used for prophylaxis or urogenital disorders such as incontinence | ARNERIC STEPHEN P (US) | 2004-06-17 | — | — | US | claimed |
| US-20030144352-A1 | Antimuscarinic aerosol | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | claimed |
| WO-2003039464-A2 | ANTIMUSCARINIC AEROSOL | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003026564-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY DISORDERS | PHARMACIA AB (SE) | 2003-04-03 | — | — | WO | claimed |
| US-20030060513-A1 | Pharmaceutical composition | PHARMACIA AB (SE) | 2003-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144352-A1 | Antimuscarinic aerosol | CHRM3, CHRM1, CHRM5 | CHRM3 1/4885CHRM2 4/4885ADRB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.